Tokujiro Yano, MD

Articles by Tokujiro Yano, MD

UFT Plus Cisplatin With Concurrent Radiotherapy for Locally Advanced Non–Small-Cell Lung Cancer

ByYukito Ichinose, MD,Tokujiro Yano, MD,Hiroshi Asoh, MD,Hideki Yokoyama, MD,Riichiroh Maruyama, MD,Chie Ushijima, MD,Tadashi Uehara, MD,Takanori Kanematsu, MD,Tomofumi Yohena, MD,Susumu Wada, MD

July 1st 1999

A phase II study of combined-modality treatment consisting of uracil and tegafur (in a molar ratio of 4:1 [UFT]) plus cisplatin (Platinol) and concurrent radiotherapy was conducted to evaluate the activity of this regimen in

UFT Plus Cisplatin in Advanced Non-Small-Cell Lung Cancer: Interim Analysis of 67 Patients

ByTokujiro Yano, MD,Shoji Kudoh, MD,Kozo Yoshimori, MD,Tetsuyuki Morikawa, MD,Mutsuo Kuba, MD,Hisanobu Niitani, MD

September 2nd 1997

A single-institution phase II study indicated that combination chemotherapy using UFT (tegafur and uracil) plus cisplatin (Platinol) in patients with non-small-cell lung cancer was active with less host toxicity than other cisplatin-

Latest Updated Articles

UFT Plus Cisplatin in Advanced Non-Small-Cell Lung Cancer: Interim Analysis of 67 Patients
Published: September 2nd 1997 | Updated:
UFT Plus Cisplatin With Concurrent Radiotherapy for Locally Advanced Non–Small-Cell Lung Cancer
Published: July 1st 1999 | Updated:

Tokujiro Yano, MD

Articles by Tokujiro Yano, MD

UFT Plus Cisplatin With Concurrent Radiotherapy for Locally Advanced Non–Small-Cell Lung Cancer

UFT Plus Cisplatin in Advanced Non-Small-Cell Lung Cancer: Interim Analysis of 67 Patients

Latest Updated Articles

Trending on CancerNetwork

Neoadjuvant Pembrolizumab/Radiotherapy Earns EU Approval in HNSCC Group

Trabedersen (OT-101) With Pembrolizumab for Newly Diagnosed PD-L1–Positive Metastatic NSCLC

What is the Impact of the SHARON Trial on Pancreatic Cancer Research?

Pembrolizumab Combo Does Not Significantly Improve OS in Unresectable HCC

Career Stage and Location Found to Impact Oncology Coverage in the US